CID-103

anti-CD38 antibody · CASI Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CID-103, covering 2025-04-03 to 2025-06-12. Get the full timeline:

Most recent: Clinical Trial Update: A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia [Phase 1, Phase 2]

See pricing